Stockreport

Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as ...

Ocean Biomedical, Inc.  (OCEA) 
PDF VRON-0200 was well tolerated, with no serious adverse events (SAEs) observed: no patients discontinued treatment one treatment related adverse event was reported (f [Read more]